Durata Therapeutics To Announce Second Quarter 2013 Financial Results On August 7, 2013

CHICAGO, July 31, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Wednesday, August 7 th at 8:30 a.m. Eastern Time to discuss second quarter 2013 financial results.

The conference call will be available via phone and webcast. To access the call, please dial 866-632-4021 for participants in the U.S. or Canada and 404-991-3968 for international callers (reference Conference ID 12148199). A replay of the call may be accessed through August 21, 2013 by dialing 800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for international callers (reference Conference ID 12148199).  The conference call will also be webcast live on the Investor Relations section of the Company's website at www.duratatherapeutics.com .

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Investor Relations and Public Affairs Contact         Allison Wey - Durata Therapeutics         Vice President, Investor Relations and Public Affairs         (312)219-7017 - awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan